Skip to Main Content

The WARMTH ACT study, performed under the auspices of WARMTH, aimed to report the safety and antitumour activity of 225Ac-PSMA RLT in patients with mCRPC who were treated in different centres across the world.

Study design and participants
MikeThis is a WARMTH-initiated multicentre retrospective study of patients with histologically diagnosed adenocarcinoma of the prostate gland who were treated with 225Ac-PSMA RLT for mCRPC at seven centres in Australia, India, Germany, and South Africa. Inclusion criteria were a diagnosis of mCRPC, PSMA-avidity in mCRPC lesions demonstrated on PET or single-photon emission computed tomography (SPECT) imaging, treatment with at least one cycle of 225Ac-PSMA RLT, and the availability of post-treatment follow-up data including PSA for PSA response assessment.

To read the full study online, click here.

WARMTH is grateful to our past president, Prof Mike M Sathekge MD, for his work as lead author on this study.